(Q90911537)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

review article

1 reference

title

The pro-tumorigenic host response to cancer therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

publication date

23 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

page(s)

667-685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Correction: Streptococcus pneumoniae Invades Erythrocytes and Utilizes Them to Evade Human Innate Immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Heparanase multiple effects in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Neutrophils in the Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Adipose tissue and adipocytes support tumorigenesis and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The hallmarks of successful anticancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Antiangiogenic therapy in oncology: current status and future directions

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Drug resistance to targeted therapies: déjà vu all over again

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The Different Mechanisms of Cancer Drug Resistance: A Brief Review.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cancer drug resistance: an evolving paradigm

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Accessories to the crime: functions of cells recruited to the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Therapy-activated stromal cells can dictate tumor fate

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy-induced metastasis: mechanisms and translational opportunities

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Radiation therapy-induced metastasis: radiobiology and clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Ionizing radiation enhances IL-6 and IL-8 production by human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The two faces of IL-6 in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Specific Decrease in B-Cell-Derived Extracellular Vesicles Enhances Post-Chemotherapeutic CD8+ T Cell Responses

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Myeloid-derived suppressor cells: linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The interaction of anticancer therapies with tumor-associated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The emerging roles of macrophages in cancer metastasis and response to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage regulation of tumor responses to anticancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Transforming growth factor-beta and the immune response: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophages in multiple myeloma: emerging concepts and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The effects of surgery on tumor growth: a century of investigations

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients?

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Potential impact of invasive surgical procedures on primary tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The Humoral Response After Laparoscopic Versus Open Colorectal Surgery: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Exploiting the critical perioperative period to improve long-term cancer outcomes

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Vascular Activation of Adhesion Molecule mRNA and Cell Surface Expression by Ionizing Radiation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS)

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Periostin Limits Tumor Response to VEGFA Inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics?

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The effect of surgical wounding on tumour development

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-β) in Patients with Breast Cancer Who Underwent Limited or Ex

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Angiogenesis and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor metastasis: molecular insights and evolving paradigms

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Emerging Biological Principles of Metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Microenvironmental regulation of metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy Enhances Metastasis Formation via VEGFR-1–Expressing Endothelial Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Recruitment of circulating breast cancer cells is stimulated by radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Effects of radiation on metastasis and tumor cell migration

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Heparanase is required for activation and function of macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Dequalinium blocks macrophage-induced metastasis following local radiation

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Peering into the aftermath: The inhospitable host?

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The mobilization and recruitment of c-kit+ cells contribute to wound healing after surgery

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Surgery, wound healing, and metastasis: recent insights and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP)

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Inflammation meets cancer, with NF-κB as the matchmaker

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Metronomic chemotherapy: new rationale for new directions

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The status of high-dose chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophages and therapeutic resistance in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Resolvins suppress tumor growth and enhance cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Hyperprogression as a distinct outcome after immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Myeloid-derived suppressor cells: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Coinhibitory Pathways in Immunotherapy for Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Cancer immunotherapy: Strategies for personalization and combinatorial approaches

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Macrophage targeting: opening new possibilities for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Combinatorial drug therapy for cancer in the post-genomic era.

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

Rationalizing combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41568-019-0209-6

7 January 2021

10.1038/S41568-019-0209-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31645711%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference